Compare Costco Wholesale Corporation (COST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Viatris Inc — how do they compare? Costco Wholesale Corporation trades at $924.08 (market cap $408.78B), while Viatris Inc trades at $16.45 (market cap $18.99B). The key difference: Costco Wholesale Corporation is far larger — about 21.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| COST | VTRS | |
|---|---|---|
Market Cap | $408.78B | $18.99B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $17.39 |
52-Week Low | $849.63 | $8.74 |
Enterprise Value | $396.92B | $31.20B |
Dividend Yield | 0.64% | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $923.9, down 0.27% with bearish technical signals but strong fundamentals. The stock shows consistent revenue growth, reaching $275.24B in 2025 with net income of $8.10B. Recent March sales surged 11.3% year-over-year to $28.41B, indicating robust business momentum. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,120 price target, though valuation metrics appear elevated with P/E at 46.37.
The investment case balances premium valuation against exceptional operational execution. Membership fee increases and expanding warehouse network drive profitability, but high P/E ratio requires sustained growth. Key risks include competitive pressure and economic sensitivity, while institutional accumulation supports long-term confidence.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
